Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

CMC Strategy for Gene Editing Systems

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

CMC Strategy for Gene Editing Systems

CMC Strategy for Gene Editing Systems: Swiss Regulatory Submissions

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in CMC for Advanced Therapy Medicinal Products (ATMPs).

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Executive Summary

A robust Chemistry, Manufacturing, and Controls (CMC) strategy is the foundation for any successful gene editing therapeutic program, particularly for sponsors targeting Swiss and EU markets. The analytical complexity of nuclease platforms (CRISPR-Cas9, base editors) and their delivery systems requires a phase-appropriate approach from the earliest stages. This involves deep characterization of all components, from guide RNA and nuclease payloads to the viral or non-viral vectors that deliver them. Aligning this analytical data package with the expectations for an Advanced Therapy Medicinal Product (ATMP) submission is a primary factor in minimizing clinical risk and adhering to accelerated timelines.

Frequently Asked Questions

How does CMC for CRISPR-based therapies differ for Swissmedic or EMA submissions compared to FDA filings?

While core scientific principles are harmonized under ICH guidelines, the regulatory framework in Europe classifies gene editing systems as ATMPs. This places significant emphasis on the Investigational Medicinal Product Dossier (IMPD), which requires a detailed Quality Target Product Profile (QTPP) and justification of the manufacturing process controls from a very early stage. Swissmedic often maintains close alignment with EMA standards for these complex next-generation therapeutics.

What are the primary analytical challenges for LNP-delivered gene editing systems?

For lipid nanoparticle (LNP) therapy, the analytical focus expands beyond the active payload. Key challenges include the rigorous characterization of the multi-component lipid system, quantifying payload (gRNA, mRNA, or RNP) encapsulation efficiency, and controlling particle size and polydispersity. Potency assays must also be developed to accurately measure the intended biological editing event in a relevant cell system.

Why is a phase-appropriate CMC strategy important for minimizing clinical risk in gene editing programs?

Establishing defined quality attributes (CQAs) and scalable manufacturing processes early prevents significant delays and regulatory questions during later clinical phases. A proactive, phase-appropriate CMC strategy ensures that the product used in IND-enabling toxicology studies is representative of future clinical material, providing a clear path toward achieving an 18-24 month IND timeline.

Defining the Analytical Foundation for Gene Editing

The manufacturing and analytical framework for gene editing systems is determined by the two core components: the editing machinery itself (e.g., CRISPR-Cas9 ribonucleoprotein) and its delivery vehicle. Each element introduces distinct variables that must be controlled and characterized to build a data package suitable for Swissmedic and other global regulatory bodies.

For non-viral delivery systems, the chemistry of the vector is a primary determinant of efficacy and safety. Innovations in biodegradable ionizable lipids, for example, directly address historical limitations in therapeutic delivery for RNA payloads (PMID: 40060499). A well-defined CMC program includes extensive characterization of these lipid components to ensure batch-to-batch consistency and a predictable performance profile.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Overcoming Delivery Barriers with Advanced Vectorology

The biological activity of a gene editing therapeutic is contingent on its ability to reach the target cell and escape endosomal compartments. The development of branched ionizable lipids (BEND) has shown a direct path to improving endosomal escape for LNP-mediated delivery of both mRNA and CRISPR-Cas9 ribonucleoprotein complexes (PMID: 39856035). This work highlights the vector’s function as an active component influencing biological outcomes.

A comprehensive CMC strategy accounts for this by integrating sophisticated analytical methods to assess vector quality attributes that correlate with function:

  • Particle Characterization: Analysis of size, charge, and morphology.

  • Payload Integrity: Verification of gRNA and mRNA/protein quality post-encapsulation.

  • Encapsulation Efficiency: Quantifying the amount of active payload successfully loaded into the LNP.

  • In Vitro Potency: Functional assays to confirm editing efficiency in a qualified cell-based model.

An Integrated Approach to Regulatory Submission

Franklin Biolabs provides the integrated CMC, analytical, and preclinical services required to advance complex gene editing programs. Our approach is built on a scientific record that includes a 100% successful IND rate since 2019, a track record established by our core scientific leadership prior to our formal launch in 2024. This expertise is housed within our >100,000 sq ft of dedicated laboratory and GxP-compliant facilities. As one biotech partner noted, our team possesses a “Vast knowledge in all aspects of vector production and analytics.”

By aligning manufacturing process development with a robust analytical strategy from the outset, we help sponsors build a comprehensive data package designed for global submissions. This integration is fundamental to de-risking development and navigating the specific requirements for ATMPs in Europe. For more information on our foundational services, see our Vector | CMC | Analytics Services overview.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities